Chain Drug Review - Marketing of Lilly’s Evista investigated
WASHINGTON — The United States Department of Justice is investigating the way Eli Lilly and Co. is marketing its drug Evista.
The criminal inquiry, which is being conducted by the Justice Department’s Office of Consumer Litigation in cooperation with the U.S. attorney’s office in Indianapolis, is investigating whether Lilly improperly promoted Evista for the prevention of breast cancer.
While growing evidence suggests that Evista may contribute to the prevention of breast cancer (as well as potentially lowering the incidence of heart disease in some older women), the drug manufacturer is prohibited from marketing the drug as a breast cancer preventative.
Related Results
Evista approvalResearch on EvistaLilly Ups Support for EvistaEvista granted priority reviewLilly’s Evista builds bone
Evista, which is known generically as raloxifene, has been approved for the prevention and treatment of osteoporosis.
According to a published report, Lilly, which recently received a criminal subpoena for its Evista-related records, believes the federal inquiry is related to the lawsuit brought against it by Astra-Zeneca LP, charging that Lilly improperly marketed Evista. That lawsuit was settled two years ago.
COPYRIGHT 2002 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
